Biomerica, Inc. (BMRA)
NCM · Medical Devices
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Peers in Medical Devices
All in industry →Abbott Laboratories
Stryker Corporation
Medtronic plc
Boston Scientific Corporation
Edwards Lifesciences Corporation
GE HealthCare Technologies Inc.
Koninklijke Philips N.V.
DexCom, Inc.
STERIS plc
Zimmer Biomet Holdings, Inc.
Recent press releases
Biomerica, Inc. has not issued a press release in this window.
SEC filings
All filings →Biomerica, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Biomerica, Inc. has no reported insider trades in the last 90 days.